Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Profound Medical ( (TSE:PRN) ) has shared an announcement.
Profound Medical announced that The Johns Hopkins Hospital has performed its first commercial, non-trial prostate cancer treatment using the company’s TULSA-PRO system, coinciding with the launch of Johns Hopkins Medicine’s new interventional MRI suite designed to turn MRI from a purely diagnostic tool into a real-time therapeutic platform. The milestone places TULSA-PRO within one of the world’s most influential prostate cancer centers, potentially accelerating adoption of the incision-free TULSA Procedure as a mainstream option for prostate cancer and enlarged prostate, and underscores a broader shift toward MRI-guided, minimally invasive therapies that promise faster recovery and fewer side effects compared with traditional surgery or radiation, with positive implications for Profound Medical’s market positioning in advanced prostate care.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its lead platform, TULSA-PRO, combines real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback to deliver precision treatment for the full spectrum of prostate disease, including prostate cancer and benign prostatic hyperplasia, while aiming to preserve urinary continence and sexual function. The company also markets Sonalleve, an MRI-guided focused ultrasound platform approved in multiple jurisdictions for non-invasive treatment of uterine fibroids, adenomyosis, certain bone tumors and pain palliation, and is exploring additional oncology and hyperthermia indications.
Average Trading Volume: 20,187
Technical Sentiment Signal: Hold
Current Market Cap: C$376.7M
For an in-depth examination of PRN stock, go to TipRanks’ Overview page.